Solid Biosciences Inc. Restructuring Reserve
Solid Biosciences Inc. (SLDB) had Restructuring Reserve of $62.00 thousand as of 2020-12-31, per its 10-K filed 2021-03-15.
Discontinued › Balance Sheet › Liabilities
us-gaap:RestructuringReserve · last filed 2021-03-15
- 2020-12-31: Restructuring Reserve $62.00K.
- 2020-09-30: Restructuring Reserve $273.00K.
- 2020-06-30: Restructuring Reserve $519.00K.
- 2020-03-31: Restructuring Reserve $981.00K.
| Period end | Restructuring Reserve |
|---|---|
| 2020-12-31 | $62.00K 10-K · filed 2021-03-15 |
| 2020-09-30 | $273.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $519.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $981.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |